// App-Quantinova.ai

P6-13-05 : Impact of olaparib versus chemotherapy on the use of strong pain medications in gBRCA-mutated HER2-negative metastatic breast cancer and associated patient reported outcomes

Researchers

Presenter

  • Chantal Merens

Principal Investigators

  • Wendy Bannister

  • Sven Bergner

  • Robert Hettle

  • Charles McCrea

  • Susan McCutcheon

  • Arnold Degboe

Medical Centers

  • Astra Zeneca, Wedel, Germany

  • AstraZeneca, Gaithersburg, MD

Locations

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Olaparib

  • Epimorph

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • NCT02000622

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved